search
Back to results

12-Week Study in Adult Subjects With Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Fluticasone Propionate
Sponsored by
Dey
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring partially controlled, uncontrolled

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A signed and dated written informed consent form prior to the conduct of any study procedures
  2. Males and females between 18 and 60 years old.
  3. Non-smoker for at least 1 year prior to Visit 1, with a smoking history of no more than 10 pack-years.
  4. Ability to understand and comply with the protocol requirements (including completion of daily PEFR, PFT and ACQ), instructions and protocol-stated restrictions.
  5. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the screening visit. WOCBP include: any female who has experienced menarche and is not post-menopausal (defined as amenorrhea for at least 12 consecutive months), or has not undergone surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation). Women who are using acceptable contraceptive medications or devices to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) will be considered WOCBP.

    WOCBP must agree to avoid becoming pregnant for the duration of the study by using adequate contraception at study entry and throughout the trial. Examples of adequate contraception include the following:

    • Norplant
    • Medroxyprogesterone acetate injection
    • Oral contraception
    • Double-barrier method (e.g., condom and spermicide)
    • Abstinence, with one of the above WOCBP will be advised to notify the Investigator of any changes in their pregnancy status or any change in contraceptive use.
  6. Agreement by subject to abide by the study protocol and its restrictions.

Exclusion Criteria:

  1. Past or present disease, excluding asthma, which as judged by the investigator, may place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives These diseases include, but are not limited to cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, diabetes type I or uncontrolled diabetes, type II, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis, COPD, eosinophilic bronchitis or pulmonary fibrosis).
  2. Clinically significant abnormalities in safety laboratory analysis at screening (Visit 1) and deemed exclusionary by the Investigator.
  3. An upper or lower respiratory tract infection within 4 weeks of Visit 1 and prior to Visit 2
  4. A history of hypersensitivity to the study drug or its components, including albuterol as rescue medication.
  5. History of illegal drug or alcohol abuse within the past 5 years.
  6. Pregnant or lactating women.
  7. Use of an investigational drug or device within 30 days prior to screening.

Sites / Locations

  • Greenville Pharmaceutical research, Inc.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Fluticasone Propionate (FP) - arm 1

Fluticasone propionate (FP) - arm 2

Fluticasone Propionate (FP) - arm 3

FLuticasone Propionate (FP) - Arm 4

Fluticasone Propionate (FP) - Arm 5

Placebo - Arm 6

Arm Description

FP BID (twice daily)

FP BID

FP BID

FP BID

FP BID

Placebo inhalation solution 2mL

Outcomes

Primary Outcome Measures

FEV1 (Forced Expiry Volume in 1 second)

Secondary Outcome Measures

Peak Expiratory Flow Rate (PEFR)

Full Information

First Posted
January 13, 2012
Last Updated
November 24, 2014
Sponsor
Dey
search

1. Study Identification

Unique Protocol Identification Number
NCT01516073
Brief Title
12-Week Study in Adult Subjects With Asthma
Official Title
A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects With Partly Controlled and Uncontrolled Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dey

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This will be a multi-center, randomized, placebo-controlled parallel-group study to evaluate nebulized fluticasone propionate (FP) dose response in adult subjects with partly controlled and uncontrolled asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-blind treatment.
Detailed Description
The primary outcome measure is FEV1 (Forced Expiry Volume in 1 second) and the secondary outcome measure is Peak Expiratory Flow Rate (PEFR), Asthma Control Questionnaire (ACQ), nighttime awakenings and reduce medication usage.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
partially controlled, uncontrolled

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
629 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fluticasone Propionate (FP) - arm 1
Arm Type
Experimental
Arm Description
FP BID (twice daily)
Arm Title
Fluticasone propionate (FP) - arm 2
Arm Type
Experimental
Arm Description
FP BID
Arm Title
Fluticasone Propionate (FP) - arm 3
Arm Type
Experimental
Arm Description
FP BID
Arm Title
FLuticasone Propionate (FP) - Arm 4
Arm Type
Experimental
Arm Description
FP BID
Arm Title
Fluticasone Propionate (FP) - Arm 5
Arm Type
Experimental
Arm Description
FP BID
Arm Title
Placebo - Arm 6
Arm Type
Placebo Comparator
Arm Description
Placebo inhalation solution 2mL
Intervention Type
Drug
Intervention Name(s)
Fluticasone Propionate
Other Intervention Name(s)
No other names are applicable
Intervention Description
FP BID for 12 weeks
Primary Outcome Measure Information:
Title
FEV1 (Forced Expiry Volume in 1 second)
Time Frame
Change in FEV1 at Week 12
Secondary Outcome Measure Information:
Title
Peak Expiratory Flow Rate (PEFR)
Time Frame
PEFR at Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A signed and dated written informed consent form prior to the conduct of any study procedures Males and females between 18 and 60 years old. Non-smoker for at least 1 year prior to Visit 1, with a smoking history of no more than 10 pack-years. Ability to understand and comply with the protocol requirements (including completion of daily PEFR, PFT and ACQ), instructions and protocol-stated restrictions. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the screening visit. WOCBP include: any female who has experienced menarche and is not post-menopausal (defined as amenorrhea for at least 12 consecutive months), or has not undergone surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation). Women who are using acceptable contraceptive medications or devices to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) will be considered WOCBP. WOCBP must agree to avoid becoming pregnant for the duration of the study by using adequate contraception at study entry and throughout the trial. Examples of adequate contraception include the following: Norplant Medroxyprogesterone acetate injection Oral contraception Double-barrier method (e.g., condom and spermicide) Abstinence, with one of the above WOCBP will be advised to notify the Investigator of any changes in their pregnancy status or any change in contraceptive use. Agreement by subject to abide by the study protocol and its restrictions. Exclusion Criteria: Past or present disease, excluding asthma, which as judged by the investigator, may place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives These diseases include, but are not limited to cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, diabetes type I or uncontrolled diabetes, type II, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis, COPD, eosinophilic bronchitis or pulmonary fibrosis). Clinically significant abnormalities in safety laboratory analysis at screening (Visit 1) and deemed exclusionary by the Investigator. An upper or lower respiratory tract infection within 4 weeks of Visit 1 and prior to Visit 2 A history of hypersensitivity to the study drug or its components, including albuterol as rescue medication. History of illegal drug or alcohol abuse within the past 5 years. Pregnant or lactating women. Use of an investigational drug or device within 30 days prior to screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Imtiaz Chaudry
Organizational Affiliation
Dey Pharma, L.P.
Official's Role
Study Director
Facility Information:
Facility Name
Greenville Pharmaceutical research, Inc.
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States

12. IPD Sharing Statement

Learn more about this trial

12-Week Study in Adult Subjects With Asthma

We'll reach out to this number within 24 hrs